

Provided by:



Plasma Cell Dyscrasias Case Conference 2022-2023

Plasma Cell Dyscrasias Case Conference 2022-2023 - 3/17/2023

March 17, 2023

12:00 AM - 1:00 PM

Perelman Center for Advanced Medicine, SPE, Conference Room 12-122

Target Audience

This program has been designed for Internal Medicine - Hematology, Internal Medicine - Medical Oncology, Pathology - Clinical

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Diagnose various plasma cell dyscrasias and distinguish between pre-cancerous (MGUS/smoldering) and malignant (multiple myeloma) conditions.
- 2 Discuss standard-of-care treatment for patients with plasma cell dyscrasias and harmonize practice patterns.
- 3 Incorporate recently published/presented research and practice guidelines into local practice and pathways.

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is approved for **1.00** contact hours
UAN Number: JA0000324-0000-23-006-L04-P

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

None

For more information, please contact
Tamieshia Nixon, Julie Mcdaniel
(215) 662-4074, (267) 970-8367

Tamieshia.Nixon@pennmedicine.upenn.edu, mcdjulie@upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant and, applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Adam Waxman, M.D.	Co-Director, Faculty	Nothing to disclose - 01/24/2023
Alfred L L. Garfall, MD, MS	Course Director	Consulting Fee-Janssen Pharmaceuticals (J&J) Consulting Fee-Amgen (Relationship has ended) Grant or research support-Novartis (Advanced Health Media) Grant or research support-Janssen Pharmaceuticals (J&J) Grant or research support-tmunity Grant or research support-crispr therapeutuics - 06/17/2022
Patricia Mangan, MSN, CRNP	Nurse Planner	Honoraria-Janssen Pharmaceuticals (J&J) Honoraria-Bristol-Myers Squibb Honoraria-Takeda Pharmaceuticals Honoraria-Glaxo Smith Kline (Relationship has ended) Honoraria-Sanofi Genzyme - 01/03/2023
Adam D. Cohen	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.- Janssen Pharmaceuticals (J&J) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Takeda Pharmaceuticals (Relationship has ended) Membership on Advisory Committees or Review Panels, Board

		Membership, etc.-Bristol-Myers Squibb Membership on Advisory Committees or Review Panels, Board Membership, etc.- Oncopeptides (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astra Zeneca Pharmaceuticals (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech Membership on Advisory Committees or Review Panels, Board Membership, etc.-Seattle Genetics (Relationship has ended) Grant or research support-Glaxo Smith Kline Membership on Advisory Committees or Review Panels, Board Membership, etc.-Glaxo Smith Kline Membership on Advisory Committees or Review Panels, Board Membership, etc.- Arcellix Grant or research support-Novartis (Advanced Health Media) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Ichnos Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer, Inc. Membership on Advisory Committees or Review Panels, Board Membership, etc.- AbbVie, Inc. (Relationship has ended) - 11/02/2022
Edward A A. Stadtmauer, MD	Other Planning Committee Member	Grant or research support-AbbVie, Inc. Consulting Fee-Glaxo Smith Kline Consulting Fee-Sanofi Genzyme Consulting Fee-Bristol-Myers Squibb Consulting Fee-Amgen - 12/20/2022
Dan T. Vogl, MD, MSCE	Other Planning Committee Member	Consulting Fee-Takeda Pharmaceuticals Consulting Fee-Glaxo Smith Kline (Relationship has ended) Consulting Fee-Karyopharm Grant or research support-Takeda Pharmaceuticals Grant or research support-Active Biotech Consulting Fee-Oncopeptides (Relationship has ended) Consulting Fee-CSL Behring (Relationship has ended) Consulting Fee-Sanofi Genzyme (Relationship has ended) - 10/05/2022
Colleen Timlin, PharmD	Pharmacy Planner	Nothing to disclose - 01/03/2023

All relevant financial relationships have been mitigated.

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit where the business lines of the ineligible company relate to the content of the activity. Financial interests are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.